Comparative Pharmacology
Head-to-head clinical analysis: TROPICAMIDE versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TROPICAMIDE versus VESICARE LS.
TROPICAMIDE vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antimuscarinic agent that blocks acetylcholine at muscarinic receptors in the ciliary muscle and sphincter muscle of the iris, resulting in mydriasis and cycloplegia.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
1-2 drops of 0.5% or 1% solution topically in the eye(s), repeated in 5 minutes if needed for maximal effect; for cycloplegic refraction, 1-2 drops of 1% solution repeated in 5 minutes.
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
Clinical Note
moderateTropicamide + Fesoterodine
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Fesoterodine."
Clinical Note
moderateTropicamide + Quinidine
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Quinidine."
Clinical Note
moderateTropicamide + Darifenacin
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Darifenacin."
Clinical Note
moderateTropicamide + Topiramate
Terminal elimination half-life is approximately 2 hours; clinically, mydriasis and cycloplegia persist for 4-8 hours despite rapid plasma clearance.
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
Primarily renal excretion of unchanged drug and metabolites; approximately 30% unchanged in urine within 6 hours; minor biliary/fecal elimination (<5%).
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category A/B
Category C
Anticholinergic
Anticholinergic
"The risk or severity of adverse effects can be increased when Tropicamide is combined with Topiramate."